Next-generation H5 influenza vaccine candidates
The table below summarizes publicly available information on next-generation influenza vaccine candidates against H5, H7, or other “pre-pandemic” influenza viruses in clinical development. Inclusion and exclusion criteria are listed at the bottom of the page.
Last updated: June 8, 2026
| Developer | Name or Formulation | Antigen(s) | Platform Technology | Delivery | Phase | Clinical Trial(s) | Key Sources |
|---|---|---|---|---|---|---|---|
| Arcturus (USA) | ARCT-2304 | H5N1 | saRNA | IM | 1 | NCT06602531 | |
Blue Willow Biologics (USA) | rH5-NE | Recombinant H5 | NanoVax adjuvanted | IN | 1 | ||
| GSK (UK) | GSK5536522 | H5N1 | mRNA | IM | 2 | ||
Moderna (USA) | mRNA-1018 | H5N8, H5-only, H5-only-CG, H7N9, H7-only | mRNA | IM | 3 | ||
Pfizer (USA) | PF-07985819 | pdmFlu unspecified | mRNA | IM | 1 | ||
Sanofi (France) | SP0289 | H5 | mRNA | IM | 1/2 | ||
Vaxart (USA) | H5 vaccine | H5 clade 2.1 H5 clade 2.3.4.4.b | Viral Vector | Oral | 1 |
Included vaccine candidates:
- Evidence for active clinical development, including data from clinical trial registries, industry R&D pipelines, funding databases, and scientific publications
- Use of next-generation platforms, such as mRNA technologies, including approaches designed to elicit broader immune responses, e.g., against all H5 viruses
Excluded vaccine candidates:
- Evidence for discontinued R&D, not in active clinical development
- Based on conventional egg- or cell-based production methods (see Taaffe 2025 and WHO 2025 for licensed H5 vaccines)